MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen - Study A - Full Text View

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00443703

Purpose

The purpose of this study is to investigate the efficacy, safety, and tolerability of an investigational treatment for patients with HIV.

Condition	Intervention	Phase
HIV Infections	Drug: raltegravir Drug: Comparator : lopinavir (+) ritonavir Drug: Comparator: placebo (unspecified)	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Efficacy Study
Official Title:	A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Ritonavir Lopinavir Raltegravir

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

HIV RNA at Week 24; safety and tolerability at week 24; change from baseline in key lipids at Week 12. [ Time Frame: Weeks 12 & 24 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Additional HIV RNA analysis and CD4 cell counts at Week 24 and at Week 48; safety and tolerability at week 48; change from baseline in key lipids at Week 24 and 48. [ Time Frame: Weeks 24 & 48 ] [ Designated as safety issue: Yes ]

Enrollment:	340
Study Start Date:	May 2007
Study Completion Date:	May 2009
Primary Completion Date:	April 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Arm 1: Drug	Drug: raltegravir raltegravir 400 mg PO b.i.d twice daily for up to 48 weeks of treatment Drug: Comparator: placebo (unspecified) lopinavir (+) ritonavir 400/100 mg PO b.i.d. Pbo twice daily for up to 48 weeks of treatment.
2: Active Comparator Arm 2: Active Comparator	Drug: Comparator : lopinavir (+) ritonavir lopinavir (+) ritonavir 400/100 mg PO b.i.d. twice daily for up to 48 weeks of treatment Drug: Comparator: placebo (unspecified) raltegravir 400 mg PO b.i.d. Pbo twice daily for up to 48 weeks of treatment

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patient is at least 18 years of age. Patient is HIV positive
Patient has documented HIV RNA <50 copies/mL for at least 3 months while on a KALETRA based regimen
Patient has been on a KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy
Patient has no documentation of HIV RNA >50 copies/mL for at least 3 months while on the KALETRA based regimen

Exclusion Criteria:

Patient is or plans to become pregnant, or nursing a child
Patient plans to donate eggs or impregnate/donate sperm.
Patient is receiving Stavudine (d4T) as a component of the background antiretroviral therapy.
Patient is currently receiving a second protease inhibitor in addition to KALETRA
Patient is currently receiving, or has received in the past twelve weeks, treatment for the management of elevated lipids
Patient has used another experimental HIV-integrase inhibitor
Patient has a current (active) diagnosis of acute hepatitis due to any cause
Patient has used systemic immunosuppressive therapy within one month prior to treatment in this study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00443703

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Additional Information:

(MedWatch - FDA maintained medical product safety Information) This link exits the ClinicalTrials.gov site

(PhRMA Clinical Study Results Database - web-based repository for clinical study results) This link exits the ClinicalTrials.gov site

(Merck: Patient & Caregiver U.S. Product Web Site) This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2007_507, MK0518-032
Study First Received:	March 2, 2007
Last Updated:	June 24, 2009
ClinicalTrials.gov Identifier:	NCT00443703 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Merck:

treatment experienced

Study placed in the following topic categories:

Sexually Transmitted Diseases, Viral
HIV Protease Inhibitors
Anti-HIV Agents
Acquired Immunodeficiency Syndrome
Antiviral Agents
Immunologic Deficiency Syndromes
Protease Inhibitors

Virus Diseases
Lopinavir
Anti-Retroviral Agents
HIV Infections
Ritonavir
Sexually Transmitted Diseases
Retroviridae Infections

Additional relevant MeSH terms:

Anti-Infective Agents
HIV Protease Inhibitors
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Anti-HIV Agents
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Immune System Diseases
Acquired Immunodeficiency Syndrome
Enzyme Inhibitors
Infection
Antiviral Agents

Pharmacologic Actions
Immunologic Deficiency Syndromes
Protease Inhibitors
Virus Diseases
Anti-Retroviral Agents
Lopinavir
HIV Infections
Ritonavir
Therapeutic Uses
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections

ClinicalTrials.gov processed this record on July 06, 2009